Opko Health, Inc.

Entera Bio reported Q3 2024 financial results, highlighting progress on EB613, the first oral PTH(1-34) tablet for osteoporosis, and its N-Tab™ platform. The company anticipates FDA's potential ruling on the ASBMR-FNIH SABRE regulatory endpoint for osteoporosis drugs in January 2025. Entera also presented new pharmacological data for EB613 at ASBMR 2024 and announced topline results for its oral oxyntomodulin tablet program with OPKO Health. Financial highlights include a net loss of $3.0 million and cash and cash equivalents of $6.9 million as of September 30, 2024.

Entera Bio and OPKO Health report positive PK/PD results for their oral oxyntomodulin tablet, showing significant systemic exposure and glucose reduction in animal models, supporting further development for obesity and metabolic disorders.